Table 2 Risk of developing selected cancers in relation to anti-HPV-16 IgG OD levels

512

201

1

1

1

411

273

1.71

1.50(1.18–1.90)

1.64(1.30–2.08)

459

472

2.63

2.38 (1.91–2.97)

2.50(2.01–3.11)

<0.0001

<0.0001*

<0.0001 ^†

798

15

1

1

1

1257

65

2.69

2.30(1.28–4.11)

2.49(1.40–4.43)

0.0007

0.005**

0.002 ^††

798

33

1

1

1

625

32

1.18

1.13(0.66–1.91)

1.09(0.64–1.83)

632

37

1.65

1.49(0.89–2.51)

1.47(0.88–2.47)

0.05

0.13***

0.13 ^†††

798

112

1

1

1

625

123

1.33

1.25(0.92–1.69)

1.26(0.94–1.70)

632

134

1.65

1.53(1.14–2.07)

1.59(1.19–2.13)

0.0006

0.0005***

0.002 ^††††

286

65

1

1

1

214

81

1.39

1.33(0.87–2.04)

1.39(0.93–2.09)

173

59

1.33

1.22(0.77–1.93)

1.33(0.86–2.07)

0.35****

0.18 ^{†††††}